How to Help Your Patients Find Vemlidy in Stock: A Provider's Guide

For providers managing patients with chronic hepatitis B, one of the most common frustrations in 2026 is the gap between prescribing Vemlidy (tenofovir alafenamide, TAF) and patients actually having the medication in hand. Access barriers — from specialty pharmacy routing confusion to prior authorization delays and sticker shock at the cash price — can disrupt treatment and put patients at risk of hepatitis B flare. This guide gives you a practical, clinical workflow to help your patients get Vemlidy reliably.

Step 1: Send the Prescription Directly to a Specialty Pharmacy

The single most effective change you can make in your prescribing workflow is to route Vemlidy prescriptions directly to a specialty pharmacy rather than sending patients to their local retail chain. This prevents the common scenario where a patient arrives at a CVS or Walgreens retail location only to be told the medication isn't in stock.

Specialty pharmacies that reliably stock and dispense Vemlidy include:

CVS Specialty — 1-800-237-2767

Walgreens Specialty — 1-800-424-6363

Accredo (Express Scripts) — 1-800-803-2523

340B pharmacies at FQHCs — for qualifying patients at federally qualified health centers, 340B pricing can dramatically reduce cost

Ask your patients which insurance plan they have before choosing a pharmacy, as some plans require use of specific in-network specialty pharmacies. A misrouted prescription can result in a claim denial even when the pharmacy has the drug in stock.

Step 2: Proactively Submit Prior Authorization

Some commercial payers require step therapy — documenting that TDF or entecavir was tried (or is clinically inappropriate) before approving Vemlidy. Getting ahead of this before the patient tries to fill the prescription prevents coverage gaps.

Strongest PA documentation for Vemlidy approval:

Recent eGFR values, especially if declining or below 60 mL/min

DXA scan showing T-score ≤-1.0 (osteopenia) or ≤-2.5 (osteoporosis)

History of TDF-related renal toxicity or bone effects

Age >60 or other comorbidities increasing TDF toxicity risk

Direct citation of AASLD/EASL preference for TAF over TDF in patients with renal or bone concerns

Step 3: Enroll Patients in Gilead's Co-Pay Assistance Program

Since 2018, over 90% of commercially insured patients enrolled in the Gilead Support Path Co-Pay Program have paid $0 for their Vemlidy prescription. The program covers up to $6,000 per year with no monthly maximum. Enrollment is straightforward — patients can register online at vemlidy.com/savings or call 1-855-769-7284.

Key program details:

Available to commercially insured patients only (not Medicare, Medicaid, TRICARE, VA)

Multilingual support available in Chinese, Korean, and Vietnamese — valuable for the HBV patient population, given disproportionate prevalence in Asian and Pacific Islander communities

Patient must be at least 18 to enroll (or an authorized representative for a minor)

Step 4: Direct Uninsured Patients to Advancing Access

For patients who are uninsured or underinsured, Gilead's Advancing Access patient assistance program provides free Vemlidy to qualifying individuals. This is particularly important for the hepatitis B patient population, which includes many uninsured immigrants and individuals with limited incomes.

Website: gileadadvancingaccess.com

Phone: 1-800-226-2056

Your care coordinator or social worker can assist patients with applications during the clinical visit

Step 5: Use medfinder When Patients Report Fill Problems

When patients report they cannot find Vemlidy at their local pharmacy, direct them to medfinder for Providers. medfinder calls pharmacies near the patient to find which ones have Vemlidy in stock and can fill the prescription — without the patient spending hours on hold. Results are texted back, so patients can go directly to a pharmacy with confirmed availability.

This is particularly valuable for patients who are elderly, have limited English proficiency, or live in areas where specialty pharmacy options are geographically spread out.

Step 6: Build a Refill Safety Net

Because stopping Vemlidy carries a boxed warning risk (severe hepatitis B exacerbation upon discontinuation), building a proactive refill safety net is essential clinical practice:

Encourage patients to refill Vemlidy 7–10 days before their supply runs out — not on the last day

Recommend mail-order for 90-day supplies, which reduces monthly refill friction

Confirm at every visit that the patient has been receiving and taking their Vemlidy — non-adherence due to access barriers is common and often unreported

Keep a template letter or PA form in your EHR for rapid Vemlidy PA submission when needed

For a full clinical briefing on Vemlidy access in 2026, see: Vemlidy Shortage: What Providers and Prescribers Need to Know in 2026.